Tumour immunology: Differing roles for MYD88 in carcinogenesis

Comment

. 2012 Oct;12(10):681.

doi: 10.1038/nri3304. Epub 2012 Sep 7.

Comment

Ezzie Hutchinson. Nat Rev Immunol. 2012 Oct.

. 2012 Oct;12(10):681.

doi: 10.1038/nri3304. Epub 2012 Sep 7.

No abstract available

Comment on

MyD88 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells.
Ochi A, Nguyen AH, Bedrosian AS, Mushlin HM, Zarbakhsh S, Barilla R, Zambirinis CP, Fallon NC, Rehman A, Pylayeva-Gupta Y, Badar S, Hajdu CH, Frey AB, Bar-Sagi D, Miller G. Ochi A, et al. J Exp Med. 2012 Aug 27;209(9):1671-87. doi: 10.1084/jem.20111706. Epub 2012 Aug 20. J Exp Med. 2012. PMID: 22908323 Free PMC article.
IL-1R-MyD88 signaling in keratinocyte transformation and carcinogenesis.
Cataisson C, Salcedo R, Hakim S, Moffitt BA, Wright L, Yi M, Stephens R, Dai RM, Lyakh L, Schenten D, Yuspa HS, Trinchieri G. Cataisson C, et al. J Exp Med. 2012 Aug 27;209(9):1689-702. doi: 10.1084/jem.20101355. Epub 2012 Aug 20. J Exp Med. 2012. PMID: 22908325 Free PMC article.

Quantifying immune-based counterselection of somatic mutations.
Yang F, Kim DK, Nakagawa H, Hayashi S, Imoto S, Stein L, Roth FP. Yang F, et al. PLoS Genet. 2019 Jul 25;15(7):e1008227. doi: 10.1371/journal.pgen.1008227. eCollection 2019 Jul. PLoS Genet. 2019. PMID: 31344031 Free PMC article.